Research GroupPresentation Abstracts(R6b) Conclusions from the MIRG 2010 BenchmarkStudy: Molecular Interactions in a Three ComponentSystem and Presentation <strong>of</strong> <strong>2011</strong> Survey Results onLabel-Free TechnologiesA.P. Yamniuk 1 , S.P. Yadav 5 , S. Bergqvist 2 , M.L. Doyle 1 ,E. Eisenstein 3 , M.K. Robinson 4 , T. Neubert 61Bristol-Myers Squibb, Princeton, NJ, United States; 2 Pfizer, LaJolla, CA, United States; 3 University Maryland BiotechnologyInstitute, Baltimore, MA, United States; 4 Fox Chase CancerCenter, Philadelphia, PA, United States; 5 Cleveland ClinicFoundation, Cleveland, OH, United States; 6 New YorkUniversity School <strong>of</strong> Medicine, New York, NY, United StatesCharacterizing the assembly <strong>of</strong> multi-protein complexes and thecompetition between multiple protein ligands for a given target arecommon challenges faced by core facilities. The MIRG2010 Benchmarkstudy was designed to assess participants’ ability to correctly describethe interactions between two protein ligands and their target proteinusing primarily biosensor technologies such as surface plasmonresonance. Participants were provided with microgram quantities <strong>of</strong>three proteins (A, B and C) and asked to determine if a ternary A-B-Ccomplex can form, or if ligands B and C bind competitively to proteinA. This presentation will summarize the conclusions from the 2010Benchmark Study, and provide perspective on the potential for futureapplication <strong>of</strong> this system as a reference standard for quantitativecharacterization <strong>of</strong> protein-protein interactions using biosensortechnologies. The field <strong>of</strong> label-free biophysical technologies likesurface plasmon resonance (SPR) and isothermal calorimetry (ITC) arebecoming indispensable in translational research and in the discoveryphase <strong>of</strong> biotherapeutics. Investigators are much more aware about thedevelopments in biomolecular interaction analysis using SPR and ITCand usefulness <strong>of</strong> these technologies in designing better drugs basedon biomolecules and vaccines. The Molecular Interaction ResearchGroup (MIRG) <strong>of</strong> <strong>ABRF</strong> has conducted an on-line survey to capture therecent explosive developments in these technologies. The survey wastargeted to both academia and pharmaceutical industry and the surveydata will be presented during the meeting.(R7) Light Microscopy Research Group (LMRG)(R7-1) Point Spread Functions, Spectral Calibration,and BeyondR. Stack, R. ColeWadsworth Center, New York State Department <strong>of</strong> Health,Albany, NY, United StatesModern light microscopes are highly evolved opto-electronicmechanicaldevices. Establishing instrument performance is crucial inensuring that reliable and accurate images can be acquired. Imagers, aswell as granting agencies, need to be confident that data collected willbe uniform and quantifiable both temporally and from instrument toinstrument. Last year, in phase-one <strong>of</strong> our world-wide research studyon instrument performance, we successfully concentrated our effortson three image-based tests: long and short term stability <strong>of</strong> illuminationsources, uniformity <strong>of</strong> field illumination, and co-registration acrossvarious wavelengths. A manuscript summarizing the phase-one studyhas been submitted to and accepted by Microscopy & Microanalysis,one <strong>of</strong> the highest rated imaging journals. In the coming year, phasetwo<strong>of</strong> our instrument performance study will focus on determining thefollowing: the point spread function <strong>of</strong> an imaging system, the system’sspectral separation ability and the spectral calibration and resolution<strong>of</strong> the detection system. As with the phase-one study, the goal <strong>of</strong> thisstudy will be neither to compare the performance <strong>of</strong> different brands<strong>of</strong> instruments, nor to ascertain which brand had better performancein a given area. Instead, the goal <strong>of</strong> our proposed phase-two study iscontinue to focus on determining the current state <strong>of</strong> modern imagingsystems through straightforward, efficient and robust tests. These testswill aid imagers in the early detection <strong>of</strong> system problems. Moreover,these tests will continue to help define relative standards that will assistboth core personnel and imagers in maintaining their instruments inoptimal operating conditions.(R7-2) Deconvolution: Core Concepts, Algorithmsand Advanced IssuesB. Northan, N. BeaversMedia Cybernetics, Guilderland, NY, United StatesDeconvolution is a computational technique used to remove blurfrom images. In this presentation image formation in the microscopewill be reviewed and it will be explained what deconvolution doesand why deconvolution is needed as a post acquisition processingstep. The concept <strong>of</strong> Point Spread Function (PSF) will be introduced.Several approaches to deconvolution and deblurring exist from simplesubtractive methods to complex iterative approaches. The majorapproaches will be examined. It will be explained why in the presence<strong>of</strong> noise a statistical approach is required. Blind deconvolution will beintroduced. The concept <strong>of</strong> Point Spread Function will be examinedin detail. The effect <strong>of</strong> microscope modality, lens parameters, andspecimen parameters on PSF shape will be discussed. Theoretical PSFcalculation and PSF measurement using beads will be reviewed withexamples. It will be explained why theoretical and measured PSFs candiffer from the true system PSF. Blind deconvolution will be furtherexamined as a tool to deal with the uncertainty <strong>of</strong> the true form <strong>of</strong>the PSF. Practical guidelines for data acquisition will be reviewed. Therelationship between sampling rate and quality <strong>of</strong> deconvolutionresults will be explained.58 • <strong>ABRF</strong> <strong>2011</strong> — Technologies to Enable Personalized Medicine
(R8) Joint Session: Proteomics Research Group(PRG) & Metabolomics Research Group (MRG)(R8a) PRG-<strong>2011</strong>: Defining the Interaction betweenUsers and Suppliers <strong>of</strong> Proteomics ServicesD. Hawke 1 , T.M. Andacht 2 , M.K. Bunger 3 , C. Bystrom 4 ,L. Dangott 5 , H. Molina 6 , R.L. Moritz 7 , R.E. Settlage 8 ,C.W. Turck 91University <strong>of</strong> Texas MD Anderson Cancer Center, Houston,TX, United States; 2 Centers for Disease Control andPrevention, Atlanta, GA, United States; 3 RTI International,Research Triangle Park, NC, United States; 4 QuestDiagnostics, San Juan Capistrano, CA, United States;5Texas A&M University, College Station, TX, United States;6Center for Genome Regulation, Barcelona, Spain; 7 Institutefor Systems Biology, Seattle, WA, United States; 8 VirginiaBioinformatics Institute, Blacksburg, VA, United States; 9 MaxPlanck Institute <strong>of</strong> Psychiatry, Munich, GermanyOver the last ten years the Proteomics Research Group (PRG) hasundertaken technical studies that have covered a wide range <strong>of</strong>issues unique to the rapidly developing field <strong>of</strong> proteomics and haveincluded a range <strong>of</strong> qualitative and quantitative experiments. The PRGstudies have resulted in a great deal <strong>of</strong> attention not only within the<strong>ABRF</strong> community but also outside as is evident from numerous articlesdealing with proteomics methods, procedures and standardization.As the field continues to develop, the diversity <strong>of</strong> instrumentationand laboratory workflows have grown in tandem. Therefore, in thePRG<strong>2011</strong> study it seemed especially useful to perform a survey tohelp the PRG define future studies based on the current blend <strong>of</strong>sample types and technologies and obtain a view <strong>of</strong> emerging trends.A survey was created to ascertain three main insights into core facilityfunction: 1) How labs interact with their clients, 2) The capacity <strong>of</strong> labsto meet the demands <strong>of</strong> their clients, and 3) The blend <strong>of</strong> experimentaltechniques <strong>of</strong>fered to and requested by clients. Survey questions weredesigned to obtain information from both users <strong>of</strong> core facilities andthe directors and personnel <strong>of</strong> core facilities. Questions covered suchtopics as the type and age <strong>of</strong> instruments in use, how data is analyzedand presented to client, sources <strong>of</strong> funding, and emerging proteomicstrends. Results are compiled en masse and presented without regardto institution. Early results reveal that about 2/3 <strong>of</strong> the responders arenot <strong>ABRF</strong> members, and at least one lab still has an operational massspectrometer that was acquired in 1990!(R8b) Metabolomics Research Group <strong>2011</strong> StudyW.R. Wik<strong>of</strong>f 1 , J.M. Asara 3 , V.V. Tolstikov 1 , P. Aronov 2 ,B. Kesler 4 , V. Shulaev 5 , C.W. Turck 61University <strong>of</strong> California Davis, Davis, CA, United States;2Stanford University, Stanford, CA, United States; 3 BethIsrael Deaconess Medical Center, Boston, MA, United States;4Thermo Fisher Scientific, Redwood City, CA, United States;5University <strong>of</strong> North Texas, Denton, TX, United States; 6 MaxPlanck Institute <strong>of</strong> Psychiatry, Munich, GermanyThe <strong>ABRF</strong> Metabolomics Research Group (MRG) was formed in2009 and aims to educate research scientists and resource facilitiesin the analytical approaches and management <strong>of</strong> data resulting fromcomprehensive metabolite studies and to promote the science andstandardization <strong>of</strong> metabolomic analyses for a variety <strong>of</strong> applications.Last year the MRG conducted a ‘Survey Study’ on the current use <strong>of</strong>metabolomics technologies and procedures in core facilities. This yearthe MRG is organizing a ‘Research Study’ involving a spiked plasmasample. The study sample consists <strong>of</strong> a human bi<strong>of</strong>luid as the matrix,replicating a typical small scale metabolomics pilot experiment thateither a core or research laboratory would perform. The sampleconsists <strong>of</strong> two groups <strong>of</strong> normal human plasma (NIST plasma ‘StandardReference Material’) with spiked in compounds. There are threebiological replicates in each group (n = 3 design) with different levels<strong>of</strong> spiked compounds differentiating the two groups. Participants areasked to determine statistical significance, fold change, and identifycompounds that differ significantly between groups A and B. The designreflects issues encountered in an actual metabolomics experimentconducted with human or animal specimens. The study is compatiblewith many methodological approaches in metabolomics, including,but not limited to LC/MS, GC/MS, NMR, as well as other methods. Aswith any metabolomics pr<strong>of</strong>iling experiment, the best results wouldbe expected using a combination <strong>of</strong> approaches. The study is the first<strong>of</strong> its kind in the field <strong>of</strong> metabolomics and is expected to produceimportant information on the strengths and limitations <strong>of</strong> the variousplatforms and technologies that are commonly used for comprehensivemetabolite analyses.Research GroupPresentation Abstracts<strong>ABRF</strong> <strong>2011</strong> — Technologies to Enable Personalized Medicine • 59
- Page 7 and 8:
Meeting SponsorsThe Association of
- Page 9 and 10: Registration ServicesRegistration S
- Page 12 and 13: Presenter InformationPresenter Info
- Page 14 and 15: AwardsABRF Annual Award for Outstan
- Page 16 and 17: ABRF Robert A. Welch Outstanding Re
- Page 18 and 19: Program-at-a-GlanceProgram-at-a-Gla
- Page 20 and 21: Sunday, February 20 (Continued)(S1-
- Page 22 and 23: Sunday, February 20 (Continued)(W3-
- Page 24 and 25: Monday, February 21 (Continued)12:0
- Page 26 and 27: Tuesday, February 22 (Continued)9:0
- Page 28 and 29: Tuesday, February 22 (Continued)(W1
- Page 30 and 31: Satellite Educational Workshop Spon
- Page 32 and 33: SW2: An Introduction to Metabolomic
- Page 34 and 35: SW4: Lean Management in Core Facili
- Page 36 and 37: Plenary Session AbstractsPlenary Se
- Page 38 and 39: Scientific Session AbstractsScienti
- Page 40 and 41: Scientific SessionAbstractsstatisti
- Page 42 and 43: Scientific SessionAbstracts(S5) Hig
- Page 44 and 45: Scientific SessionAbstracts(S7-2) S
- Page 46 and 47: Workshop Session AbstractsWorkshop
- Page 48 and 49: Workshop SessionAbstractscase incor
- Page 50 and 51: Workshop SessionAbstracts(W7) Cellu
- Page 52 and 53: Workshop SessionAbstractsresolution
- Page 54 and 55: (W14-3) Galaxy Next Generation Sequ
- Page 56 and 57: Research Group Presentation Abstrac
- Page 58 and 59: Research GroupPresentation Abstract
- Page 62 and 63: Poster Session Abstracts**ABRF Post
- Page 64 and 65: Poster Abstractsglobal gene express
- Page 66 and 67: Poster Abstractsdiscussions of cont
- Page 68 and 69: Poster Abstractspossible applicatio
- Page 70 and 71: Poster Abstracts129 Bravo Automated
- Page 73 and 74: distribution. Additionally, we show
- Page 75 and 76: Illumina Genome Analyzer. PicoPlex
- Page 77 and 78: uniformity, reproducibility of enri
- Page 79 and 80: kits for Tempus TM and PAXgene® st
- Page 81 and 82: 165 Benchmarking miRNA ExpressionLe
- Page 83 and 84: Phoenix crystallography robot and a
- Page 85 and 86: Laboratory is located next door and
- Page 87 and 88: data of a Thermo Orbitrap instrumen
- Page 89 and 90: **197 Multi-Functional Superparamag
- Page 91 and 92: pattern of N-linked glycans in form
- Page 93 and 94: advantage of using two separate 15
- Page 95 and 96: allowed absolute quantitation. Comp
- Page 97 and 98: levels between the animal groups. A
- Page 99 and 100: MuDPIT, and off-gel electrophoresis
- Page 101 and 102: 237 Multi-Site Assessment of Proteo
- Page 103 and 104: with good limits of quantification
- Page 105 and 106: 249 Rapid Monoclonal Antibody Glyca
- Page 107 and 108: OOng, J. - 117PPatel, S. - 169Peake
- Page 109 and 110: AnaSpec, Eurogentec Group Booth 417
- Page 111 and 112:
FASEB MARC Program Booth 4169650 Ro
- Page 113 and 114:
IntegenX, Inc. Booth 2015720 Stoner
- Page 115 and 116:
Nonlinear Dynamics Booth 1052530 Me
- Page 117 and 118:
Roche Applied Science Booth 5009115
- Page 119 and 120:
Exhibit Hall FloorplanGrand Oaks Ba
- Page 121 and 122:
Exhibitor List in Booth OrderExhibi
- Page 123 and 124:
This workshop will present ways to
- Page 125 and 126:
Grand Oaks Ballroom,Rooms P&Q, Leve
- Page 127 and 128:
NotesNotesABRF 2011 — Technologie
- Page 129 and 130:
Tuesday, February 22 — 12:00 pm -
- Page 131 and 132:
MARCH 16-20, 2012 • DISNEY’S CO